{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Torisel+%28Temsirolimus%29&page=2", "query": { "intervention": "Torisel (Temsirolimus)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Torisel+%28Temsirolimus%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-25T21:31:05.722Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07811297", "title": "A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Endometrial Neoplasms", "Ovarian Neoplasms", "Soft Tissue Sarcoma (STS)", "Glioblastoma" ], "interventions": [ { "name": "AL58805", "type": "DRUG" }, { "name": "AL3818", "type": "DRUG" }, { "name": "Temozolomide (TMZ)", "type": "DRUG" }, { "name": "CCNU", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advenchen Pharmaceuticals, LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 138, "start_date": "2026-09-01", "completion_date": "2031-09-01", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-09-25T21:31:05.722Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07811297" }, { "nct_id": "NCT03324373", "title": "Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Partial or Radical Cytoreductive Nephrectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Yousef Zakharia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2019-03-20", "completion_date": "2024-08-28", "has_results": false, "last_update_posted_date": "2025-04-24", "last_synced_at": "2026-09-25T21:31:05.722Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT03324373" }, { "nct_id": "NCT00784979", "title": "Panel Reactive Antibody (PRA) Reduction in Sensitized Patients Awaiting Renal Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "End Stage Renal Disease" ], "interventions": [ { "name": "CMVIG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tampa General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2002-01", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2015-06-29", "last_synced_at": "2026-09-25T21:31:05.722Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00784979" }, { "nct_id": "NCT00693433", "title": "Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Refractory Multiple Myeloma", "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage III Multiple Myeloma" ], "interventions": [ { "name": "dexamethasone", "type": "DRUG" }, { "name": "temsirolimus", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2008-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-12-04", "last_synced_at": "2026-09-25T21:31:05.722Z", "location_count": 1, "location_summary": "Las Angeles, California", "locations": [ { "city": "Las Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00693433" }, { "nct_id": "NCT01364844", "title": "Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Colorectal Cancer", "Endometrial Cancer" ], "interventions": [ { "name": "DS-7423", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2011-07", "completion_date": "2013-11", "has_results": false, "last_update_posted_date": "2014-02-25", "last_synced_at": "2026-09-25T21:31:05.722Z", "location_count": 3, "location_summary": "Detroit, Michigan • New York, New York • Nashville, Tennessee", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01364844" }, { "nct_id": "NCT00895583", "title": "Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Graft Rejection", "Kidney Transplant", "Renal Allograft Recipients", "Renal Transplant" ], "interventions": [ { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 254, "start_date": "2009-06", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2014-09-18", "last_synced_at": "2026-09-25T21:31:05.722Z", "location_count": 25, "location_summary": "La Jolla, California • San Francisco, California • Aurora, Colorado + 19 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00895583" }, { "nct_id": "NCT00060645", "title": "Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumors", "Lymphoma", "Multiple Myeloma" ], "interventions": [ { "name": "ridaforolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2003-05", "completion_date": "2009-02", "has_results": false, "last_update_posted_date": "2015-08-27", "last_synced_at": "2026-09-25T21:31:05.722Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00060645" }, { "nct_id": "NCT02891603", "title": "A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Graft Vs Host Disease", "GVHD" ], "interventions": [ { "name": "Pacritinib", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Allogenic hematopoietic cell transplant (alloHCT)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2017-06-08", "completion_date": "2022-04-18", "has_results": true, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-09-25T21:31:05.722Z", "location_count": 2, "location_summary": "Tampa, Florida • Minneapolis, Minnesota", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02891603" }, { "nct_id": "NCT01822015", "title": "Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "Sirolimus", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2013-03-15", "completion_date": "2019-12-12", "has_results": false, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-09-25T21:31:05.722Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01822015" }, { "nct_id": "NCT04895748", "title": "DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "DFF332", "type": "DRUG" }, { "name": "RAD001", "type": "DRUG" }, { "name": "PDR001", "type": "DRUG" }, { "name": "NIR178", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 40, "start_date": "2021-11-30", "completion_date": "2026-02-13", "has_results": false, "last_update_posted_date": "2026-03-03", "last_synced_at": "2026-09-25T21:31:05.722Z", "location_count": 5, "location_summary": "Duarte, California • Boston, Massachusetts • St Louis, Missouri + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04895748" } ] }